Combined targeting of PSMB8 and Menin leads to synergistic anti-proliferative effects, eradicates KMT2A-r leukemia in patient-derived xenografts and prevents development of Menin-inhibitor resistance in AML. This evidence concerns the gene PSMB8 and acute myeloid leukemia.